garenoxacin has been researched along with Breast Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, Y; Kashiwagi, S; Nagayama, K; Noda, S; Ogawa, K; Ohira, M; Onoda, N; Takahashi, K; Takahashi, M; Takashima, T | 1 |
1 other study(ies) available for garenoxacin and Breast Neoplasms
| Article | Year |
|---|---|
Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Female; Fluoroquinolones; Follow-Up Studies; Humans; Middle Aged; Moxifloxacin; Neoadjuvant Therapy; Off-Label Use; Prior Authorization; Retrospective Studies; Risk Factors; Treatment Outcome | 2019 |